Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | |
Product Type | Organoid |
Tissue | Lung alveoli, Bronchi |
Disease | Non-Small Cell Lung Cancer |
Applications
Drug Test (Organoid Only)
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Using Immune Cell Co-culture
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Using Cancer Associate Fibroblast
Establishing a process for isolating cytotoxic T cells that can directly attack cancer cells, creating an MHC-TCR
interaction environment, and utilizing MHC I/II blockers to achieve an immune microenvironment in vivo.
Our lung cancer organoids accurately replicate patient tumors by expressing key markers TTF-1, CK7, p40 and CK5/6, underscoring their fidelity for cancer research and personalized treatment development. This molecular mimicry enables a profound understanding of lung cancer pathology and offers a promising avenue for therapeutic innovations.
Lung cancer organoid
H&E | TTF-1 | CK7 | p40 (ΔNp63) | CK5/6 | |
|---|---|---|---|---|---|
Cancer tissue Adenocarcinoma |  |  |  |  |  |
Cancer tissue Adenosquamous |  |  |  |  |  |
Cancer organoid Adenocarcinoma |  |  |  |  |  |
Cancer organoid Adenosquamous |  |  |  |  |  |
Unlock the essence of precision in cancer treatment with our lung cancer organoids, mirroring the genetic markers of lung cancer. Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing Dive into a new era of oncology, where your individuality guides our innovation.
Utilizing a database of protein interactions and mutations, we statistically analyze genetic correlations to identify significant relationships in lung cancer organoids.
Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.
Cisplatin |  |  |  |  |  |
Ctr | 1μM | 3μM | 12μM | 50μM | |
Carboplatin |  |  |  |  |  |
Ctr | 1μM | 3μM | 12μM | 50μM | |
Gemcitabine |  |  |  |  |  |
Ctr | 0.03μM | 0.125μM | 0.5μM | 2μM | |
Paclitaxel |  |  |  |  |  |
Ctr | 0.25μM | 0.5μM | 1μM | 20μM |
Carboplatin
Cisplatin
Gemcitabine
Paclitaxel
Drug responses of patient-derived colorectal cancer organoids.
Dose-response curves generated from patient-derived colorectal cancer organoid lines treated with oxaliplatin, Irinotecan and 5-FU.
These figures demonstrate the percent of cell viability measured.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
